Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia
Puig Grifol, Núria ![ORCID Identifier](/img/uab/orcid.ico)
(Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Miñambres, Inka ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Benitez, Sonia ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Gil, Pedro ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Grau-Agramunt, Margarida (Institut d'Investigació Biomèdica Sant Pau)
Rivas-Urbina, Andrea ![ORCID Identifier](/img/uab/orcid.ico)
(Institut d'Investigació Biomèdica Sant Pau)
Pérez Pérez, Antonio
(Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Sanchez-Quesada, Jose Luis
(Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas)
Date: |
2020 |
Abstract: |
Lipoprotein characteristics were analyzed in familial combined hyperlipidemia (FCH) patients before and after statin treatment. Twenty-six FCH patients were classified according to the presence (HTG group, n = 13) or absence (normotriglyceridemic (NTG) group, n = 13) of hypertriglyceridemia. Fifteen healthy subjects comprised the control group. Lipid profile, inflammation markers, and qualitative characteristics of lipoproteins were assessed. Both groups of FCH subjects showed high levels of plasma C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and apolipoprotein J. Statins reverted the increased levels of Lp-PLA2 and CRP. Lipoprotein composition alterations detected in FCH subjects were much more frequent in the HTG group, leading to dysfunctional low-density lipoproteins (LDL) and high-density lipoproteins (HDL). In the HTG group, LDL was smaller, more susceptible to oxidation, and contained more electronegative LDL (LDL(-)) compared to the NTG and control groups. Regarding HDL, the HTG group had less Lp-PLA2 activity than the NTG and control groups. HDL from both FCH groups was less anti-inflammatory than HDL from the control group. Statins increased LDL size, decreased LDL(-), and lowered Lp-PLA2 in HDL from HTG. In summary, pro-atherogenic alterations were more frequent and severe in the HTG group. Statins improved some alterations, but many remained unchanged in HTG. |
Grants: |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-1149
|
Note: |
Altres ajuts: MSCBS/FIS/PI13/00364 |
Note: |
Altres ajuts: MSCBS/FIS/PI16/00471 |
Rights: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. ![Creative Commons](/img/licenses/by.ico) |
Language: |
Anglès |
Document: |
Article ; recerca ; Versió publicada |
Subject: |
Familial combined hyperlipidemia ;
Lipoproteins ;
Lipoprotein function ;
Inflammation ;
Triglycerides |
Published in: |
Biomedicines, Vol. 8, Num. 1 (January 2020) , art. 6, ISSN 2227-9059 |
DOI: 10.3390/biomedicines8010006
PMID: 31935793
The record appears in these collections:
Research literature >
UAB research groups literature >
Research Centres and Groups (research output) >
Health sciences and biosciences >
Institut de Recerca Sant PauArticles >
Research articlesArticles >
Published articles
Record created 2020-07-06, last modified 2023-11-30